68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is
overexpressed in cancer-associated fibroblasts and some inflammation. Thus this prospective
study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy
response assessment and follow-up of SAPHO than 18F-FDG PET/CT.